相关实验视频

Updated: Jan 16, 2026

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

在T细胞采用转移型大肠炎模型中,CCL20/CCR6调节剂的影响

Marika Allodi¹, Lisa Flammini¹, Carmine Giorgio¹

¹Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma, Italy.

Pharmaceuticals (Basel, Switzerland)

|September 27, 2025

概括

针对CCL20/CCR6轴的MR120和MR452在采用转移性结肠炎模型中显示出有限的疗效,尽管减少了炎症标志物. 这表明轴可能不是这个特定的IBD模型的主要治疗点.

科学领域:

胃肠病学胃肠病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

炎症性肠病 (IBD) 是一种慢性炎症状况,原因不明.
在IBD病变发生过程中,CCL20/CCR6信号通路至关重要.
用小分子调节这个轴提供了一个潜在的治疗策略.

研究的目的:

在采用转移性结肠炎模型中评估MR120 (CCR6抗剂) 和其衍生物MR452的疗效.
使用该模型,研究CCL20/CCR6轴在IBD病原发生中的作用.

主要方法:

通过通过CD4+CD25-T细胞的采用转移诱导免疫受损小鼠的结肠炎.
每天进行皮下注射MR120或MR452,持续8周.
评估疾病活动,结肠厚,炎症评分和髓氧化酶活性.

主要成果:

无论是MR120还是MR452都显示出有限的保护作用,无法防止疾病活动和炎症的增加.
化合物降低了结肠髓氧化酶活性;MR452还降低了肠道CCL20水平.
没有观察到IBD类表型的显著改善.

结论:

在采用转移性结肠炎模型中,CCL20/CCR6轴的药理学向的影响可以忽略不计.
在其他结肠炎模型中MR120的有效性并不能转化为这种特定的IBD模型.
改变的免疫平衡和破坏的Treg功能可能会限制在IBD中准这一轴的治疗潜力.

关键词:

在CCL20/CCR6中使用.这是一种CCR6抗剂.收养转移性大肠炎肠道炎症是一种肠道炎症.

更多相关视频

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...